The impact of PD-L1 upregulation on MM cells with ambient IFN-γ should be clarified in patients with MM receiving these IMiDs, especially in combination with therapeutic antibodies for augmentation of ADCC activity. This evidence concerns the gene IFNG and Miyoshi myopathy.